A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

NCT03125876 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Company strategy adjustment

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: CT053PTSA

Sponsor

Sunshine Lake Pharma Co., Ltd.